Skip to main content
. Author manuscript; available in PMC: 2022 Jan 20.
Published in final edited form as: Aliment Pharmacol Ther. 2020 Oct 21;52(11-12):1658–1675. doi: 10.1111/apt.16119

Figure 4:

Figure 4:

Nonresponder imputation analysis of symptomatic remission†, ‡, §, ¶ from Week 44 through Week 92 for all patients randomized to ustekinumab in the maintenance study and treated in the long-term extension (A) and by biologic treatment history subgroup (B)